Literature DB >> 29191357

Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study.

Milos Brankovic1, K Martijn Akkerhuis2, Nick van Boven2, Sharda Anroedh2, Alina Constantinescu2, Kadir Caliskan2, Olivier Manintveld2, Jan Hein Cornel3, Sara Baart2, Dimitris Rizopoulos4, Hans Hillege5, Eric Boersma2, Victor Umans3, Isabella Kardys6.   

Abstract

Renal dysfunction is an important component of chronic heart failure (CHF), but its single assessment does not sufficiently reflect clinically silent progression of CHF prior to adverse clinical outcome. Therefore, we aimed to investigate temporal evolutions of glomerular and tubular markers in 263 stable patients with CHF, and to determine if their patient-specific evolutions during this clinically silent period can dynamically predict clinical outcome. We determined the risk of clinical outcome (composite endpoint of Heart Failure hospitalization, cardiac death, Left Ventricular Assist Device placement, and heart transplantation) in relation to marker levels, slopes and areas under their trajectories. In each patient, the trajectories were estimated using repeatedly measured glomerular markers: creatinine/estimated glomerular filtration rate (eGFR), cystatin C (CysC), and tubular markers: urinary N-acetyl-beta-D-glucosaminidase (NAG) and kidney injury molecule (KIM)-1, plasma and urinary neutrophil gelatinase-associated lipocalin (NGAL). During 2.2 years of follow-up, we collected on average 8 urine and 9 plasma samples per patient. All glomerular markers predicted the endpoint (univariable hazard ratio [95% confidence interval] per 20% increase: creatinine: 1.18[1.07-1.31], CysC: 2.41[1.81-3.41], and per 20% eGFR decrease: 1.13[1.05-1.23]). Tubular markers, NAG, and KIM-1 also predicted the endpoint (NAG: 1.06[1.01-1.11] and KIM-1: 1.08[1.04-1.11]). Larger slopes were the strongest predictors (creatinine: 1.57[1.39-1.84], CysC: 1.76[1.52-2.09], eGFR: 1.59[1.37-1.90], NAG: 1.26[1.11-1.44], and KIM-1: 1.64[1.38-2.05]). Associations persisted after multivariable adjustment for clinical characteristics. Thus, during clinically silent progression of CHF, glomerular and tubular functions deteriorate, but not simultaneously. Hence, patient-specific evolutions of these renal markers dynamically predict clinical outcome in patients with CHF.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  dynamic prediction; heart failure; individual risk; renal dysfunction; temporal evolution; tubular markers

Mesh:

Substances:

Year:  2017        PMID: 29191357     DOI: 10.1016/j.kint.2017.09.013

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Evaluation of cystatin C and neutrophil gelatinase-associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip).

Authors:  Oliver Dörr; Claudia Walther; Christoph Liebetrau; Till Keller; Regine M Ortlieb; Niklas Boeder; Pascal Bauer; Helge Möllmann; Luise Gaede; Christian Troidl; Sandra Voss; Timm Bauer; Christian W Hamm; Holger Nef
Journal:  Clin Cardiol       Date:  2018-11-16       Impact factor: 2.882

Review 2.  Utility of Urine Biomarkers and Electrolytes for the Management of Heart Failure.

Authors:  Frederik Hendrik Verbrugge
Journal:  Curr Heart Fail Rep       Date:  2019-12

3.  Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failure-The Bio- SH i FT Study.

Authors:  Elke Bouwens; Milos Brankovic; Henk Mouthaan; Sara Baart; Dimitris Rizopoulos; Nick van Boven; Kadir Caliskan; Olivier Manintveld; Tjeerd Germans; Jan van Ramshorst; Victor Umans; K Martijn Akkerhuis; Isabella Kardys
Journal:  J Am Heart Assoc       Date:  2019-02-19       Impact factor: 5.501

4.  Circulating Biomarkers of Cell Adhesion Predict Clinical Outcome in Patients with Chronic Heart Failure.

Authors:  Elke Bouwens; Victor J van den Berg; K Martijn Akkerhuis; Sara J Baart; Kadir Caliskan; Jasper J Brugts; Henk Mouthaan; Jan van Ramshorst; Tjeerd Germans; Victor A W M Umans; Eric Boersma; Isabella Kardys
Journal:  J Clin Med       Date:  2020-01-10       Impact factor: 4.241

5.  Personalized screening intervals for kidney function in patients with chronic heart failure: a modeling study.

Authors:  Anne-Sophie Schuurman; Anirudh Tomer; K Martijn Akkerhuis; Ewout J Hoorn; Jasper J Brugts; Olivier C Manintveld; Jan van Ramshorst; Victor A Umans; Eric Boersma; Dimitris Rizopoulos; Isabella Kardys
Journal:  J Nephrol       Date:  2021-03-18       Impact factor: 4.393

6.  Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study).

Authors:  Dominika Klimczak-Tomaniak; Marie de Bakker; Elke Bouwens; K Martijn Akkerhuis; Sara Baart; Dimitris Rizopoulos; Henk Mouthaan; Jan van Ramshorst; Tjeerd Germans; Alina Constantinescu; Olivier Manintveld; Victor Umans; Eric Boersma; Isabella Kardys
Journal:  Sci Rep       Date:  2022-02-18       Impact factor: 4.379

7.  Renal tubular damage and worsening renal function in chronic heart failure: Clinical determinants and relation to prognosis (Bio-SHiFT study).

Authors:  Milos Brankovic; K Martijn Akkerhuis; Ewout J Hoorn; Nick van Boven; Jan C van den Berge; Alina Constantinescu; Jasper Brugts; Jan van Ramshorst; Tjeerd Germans; Hans Hillege; Eric Boersma; Victor Umans; Isabella Kardys
Journal:  Clin Cardiol       Date:  2020-04-16       Impact factor: 2.882

8.  Temporal patterns of macrophage- and neutrophil-related markers are associated with clinical outcome in heart failure patients.

Authors:  Dominika Klimczak-Tomaniak; Elke Bouwens; Anne-Sophie Schuurman; K Martijn Akkerhuis; Alina Constantinescu; Jasper Brugts; B Daan Westenbrink; Jan van Ramshorst; Tjeerd Germans; Leszek Pączek; Victor Umans; Eric Boersma; Isabella Kardys
Journal:  ESC Heart Fail       Date:  2020-03-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.